再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新

智通财经网11-05

智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www....

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581944767?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-05 08:04","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2581944767","market":"hk","top_or_hot":-1,"title":"再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www....</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1365318.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-05 08:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1365318.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www....</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1365318.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1365318.html","article_id":"2581944767","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581944767","pubTimestamp":1762301064,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","AMGN":"安进","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK1588":"回港中概股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK1161":"生物科技","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","BK4581":"高盛持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4531":"中概回港概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4526":"热门中概股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","BK4139":"生物科技","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","ZLAB":"再鼎医药","BK4599":"减肥药","BK4566":"资本集团","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","09688":"再鼎医药","BK4585":"ETF&股票定投概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4548":"巴美列捷福持仓","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD"},"translate_title":"Zai Lab (09688): Update on Amgen's Phase 1b/3 Clinical Study of Bematuzumab FORTITUDE-102","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1.5,"AMGN":1.5,"ZLAB":1.5},"content_text":"智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581944767","isCrawlerRequest":true}